Identification and Validation of a Novel Antibacterial Compound MZ-01 against Methicillin-Resistant

Junshu Yang, Christopher Brown, Wayland Noland, Timothy J Johnson, Yinduo Ji

Abstract read

In one paragraph

Article in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

Green and Ecofriendly Mycosynthesis of Nanocomposite Based on Zinc and Magnesium Oxide Nanoparticles Using Endophytic Sarocladium kiliense: Characterization, Anticancer Activity, Antimicrobial and Antibiofilm Activities.MicrobiologyOpen · 2026
Article
Broad-Spectrum Antibacterial Activity of Antioxidant Octyl Gallate and Its Impact on Gut Microbiome.Antibiotics (Basel, Switzerland) · 2024
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Junshu YangDepartment of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN 55108, USA.

Christopher BrownDepartment of Chemistry, University of Minnesota, Minneapolis, MN 55454, USA.

Wayland NolandDepartment of Chemistry, University of Minnesota, Minneapolis, MN 55454, USA.

Timothy J JohnsonDepartment of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN 55108, USA.

Yinduo JiDepartment of Veterinary and Biomedical Sciences, University of Minnesota, St. Paul, MN 55108, USA.ORCID 0000-0002-0199-0195

Funding

College of veterinary medicine at the University of Minnesota USDA General Agricultural Research fund MIN-63-119National Institute of Allergy and Infectious Diseases AI07895

6 · The paper itself

Abstract

The discovery of new classes of antibiotics is slow, and it is being greatly outpaced by the development of bacterial resistance. This disparity places us in an increasingly vulnerable position because we are running out of safe and effective therapeutic options to treat antibiotic-resistant infections. This is exemplified by the emergence and persistence of hospital-acquired and community-associated methicillin-resistant

Indexed as

antimicrobial agentsGram-positive bacterial pathogenMRSAStaphylococcus aureus

Identifiers

PMID36358205

DOI10.3390/antibiotics11111550

PMCPMC9686779

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.